Commentary|Videos|March 14, 2026

Chemotherapy vs Biomarker-Driven Models in Lymphoma

Fact checked by: Paige Britt

MRD testing in lymphoma grows fast, but varying assays and limited guidelines leave clinicians guessing; trials and standards clarify care.

In an interview with Targeted Oncology, Hua-Jay “Jeff” Cherng, MD, assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discussed the biggest hurdles in moving from standard chemotherapy to biomarker-driven models in treating patients with lymphoma.


Latest CME